Beijing Wandong Medical Technology Co Ltd

The company maintains a strong liquidity position, as evidenced by a current ratio of 10.2, indicating that it has significantly more current assets than current liabilities. However, its operating cash flow of 1.1 million CNY is relatively low compared to its total assets of 5.3 billion CNY, suggesting limited cash generation from operations. The price-to-book ratio of 1.97 and the price-to-tangible-book ratio of 1.97 indicate that the company's market value is slightly above its book value, but not significantly so. In terms of profitability, the company's return on equity (ROE) of 1.09% and return on assets (ROA) of 0.97% are below the typical thresholds for strong performance in the healthcare equipment industry. The net income of 51.5 million CNY and operating income of 64.3 million CNY suggest modest profitability, but the company's gross profit of 155.8 million CNY indicates that it is managing to maintain a reasonable margin on its sales. The company's revenue is concentrated in a single business segment, as no specific segments are disclosed in the available data. Geographically, the company is based in China, and there is no indication of significant international operations or revenue diversification. Looking at the company's growth trajectory, the available data does not provide specific forward-looking revenue projections or growth rates for the current or next fiscal year. However, the company's revenue of 391.6 million CNY and net income of 51.5 million CNY suggest a stable but not rapidly growing business. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio is 0.0, indicating that it is not leveraged and has no long-term debt obligations. However, the company has a negative net cash position after subtracting total debt, which could be a concern for liquidity. Recent events and filings do not provide specific details on the company's recent activities or strategic initiatives. Analysts have provided a mean recommendation of 2.00, which is a "Buy" rating, with one analyst recommending a "Buy" and no analysts recommending a "Strong Buy" or "Sell".